{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:14:53Z","timestamp":1780496093004,"version":"3.54.1"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1111\/ane.12803","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T10:59:31Z","timestamp":1500980371000},"page":"29-32","source":"Crossref","is-referenced-by-count":14,"title":["Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy"],"prefix":"10.1155","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"S.","family":"Lattanzi","sequence":"first","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cagnetti","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Foschi","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Provinciali","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Silvestrini","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Department of Experimental and Clinical Medicine; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"10.1111\/ane.12803-BIB0001|ane12803-cit-0001","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"key":"10.1111\/ane.12803-BIB0002|ane12803-cit-0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1756285615589711","article-title":"A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures","volume":"8","author":"Rocamora","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1111\/ane.12803-BIB0003|ane12803-cit-0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"League against epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International","year":"1981","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12803-BIB0004|ane12803-cit-0004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"League against epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International","year":"1989","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12803-BIB0005|ane12803-cit-0005","unstructured":"Eslicarbazepine acetate summary of product characteristics 2014 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf"},{"key":"10.1111\/ane.12803-BIB0006|ane12803-cit-0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1212\/WNL.0000000000000619","article-title":"Seizure course during pregnancy in catamenial epilepsy","volume":"83","author":"Cagnetti","year":"2014","journal-title":"Neurology"},{"key":"10.1111\/ane.12803-BIB0007|ane12803-cit-0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2015.03.003","article-title":"Lacosamide monotherapy for partial onset seizures","volume":"27","author":"Lattanzi","year":"2015","journal-title":"Seizure"},{"key":"10.1111\/ane.12803-BIB0008|ane12803-cit-0008","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pjnns.2017.03.003","article-title":"Lacosamide during pregnancy and breastfeeding","volume":"51","author":"Lattanzi","year":"2017","journal-title":"Neurol Neurochir Pol"},{"key":"10.1111\/ane.12803-BIB0009|ane12803-cit-0009","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1212\/WNL.0000000000001585","article-title":"Time to prerandomization monthly seizure count in perampanel trials: a novel epilepsy endpoint","volume":"84","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1111\/ane.12803-BIB0010|ane12803-cit-0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12803-BIB0011|ane12803-cit-0011","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.eplepsyres.2014.06.017","article-title":"Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study","volume":"108","author":"Correia","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12803-BIB0012|ane12803-cit-0012","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","article-title":"Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis","volume":"86","author":"Lattanzi","year":"2016","journal-title":"Neurology"},{"key":"10.1111\/ane.12803-BIB0013|ane12803-cit-0013","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12803-BIB0014|ane12803-cit-0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1111\/ane.12803-BIB0015|ane12803-cit-0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/9781444316667.ch38","volume-title":"The Treatment of Epilepsy","author":"Almeida","year":"2009","edition":"3"},{"key":"10.1111\/ane.12803-BIB0016|ane12803-cit-0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1111\/ane.12803-BIB0017|ane12803-cit-0017","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/brain\/awu339","article-title":"Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug","volume":"138","author":"Doeser","year":"2015","journal-title":"Brain"},{"key":"10.1111\/ane.12803-BIB0018|ane12803-cit-0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2013.11.022","article-title":"The effects of eslicarbazepine on persistent Na\u207a current and the role of the Na\u207a channel \u03b2 subunits","volume":"108","author":"Doeser","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12803-BIB0019|ane12803-cit-0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers","volume":"54","author":"Nunes","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12803-BIB0020|ane12803-cit-0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.12574","article-title":"Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy","volume":"134","author":"Holtkamp","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12803-BIB0021|ane12803-cit-0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","article-title":"Therapeutics and technology assessment subcommittee of the American academy of neurology; quality standards subcommittee of the American academy of neurology; American epilepsy society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society","volume":"62","author":"French","year":"2004","journal-title":"Neurology"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12803\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:50:44Z","timestamp":1671540644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12803","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}